ADORA3 and glaucoma: Many A1AR agonists, A2aAR agonists, and A3AR agonists are potentially therapeutic candidates for treating inflammatory diseases such as glaucoma by decreasing IOP and inducing specific anti-inflammatory effects [36,37].